Story perspectives

Novartis and Genentech Sue Over Illegal Xolair Imports

2/27/2026

Summary

Story summary

Novartis and Genentech filed a lawsuit against SHARx and a Canadian pharmacy for illegal Xolair imports.
The suit alleges FDA regulation violations and patient safety risks from Xolair's storage sensitivity.
It also highlights alternative funding programs (AFPs) operating in a legal gray area.
Novartis's stock fell 0.80% as investors worried about legal challenges and regulatory scrutiny.
The outcome could set a precedent for FDA enforcement, affecting drug pricing and access.

1 of 1

Story summary

Novartis and Genentech filed a lawsuit against SHARx and a Canadian pharmacy for illegal Xolair imports.
The suit alleges FDA regulation violations and patient safety risks from Xolair's storage sensitivity.
It also highlights alternative funding programs (AFPs) operating in a legal gray area.
Novartis's stock fell 0.80% as investors worried about legal challenges and regulatory scrutiny.
The outcome could set a precedent for FDA enforcement, affecting drug pricing and access.